Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Youichi Makari"'
Autor:
Yutaka Kimura, Hisato Kawakami, Masahiro Goto, Youichi Makari, Takao Tamura, Naotoshi Sugimoto, Jin Matsuyama, Yukinori Kurokawa, Toshimasa Tsujinaka, Daisuke Sakai, Shunji Endo, Kazumasa Fujitani, Yusuke Akamaru, Toshio Shimokawa, Shigeyuki Tamura, Taroh Satoh
Publikováno v:
International Journal of Clinical Oncology. 25:1635-1643
We previously reported the HERBIS-4A phase II trial comparing S-1 plus cisplatin (SP) with capecitabine plus cisplatin (XP) in chemotherapy-naive patients with HER2-negative advanced gastric cancer (GC). We performed a pooled analysis of HERBIS-4A an
Autor:
Hidemi, Nishi, Yoichi, Ohtake, Takayuki, Toh, Hoshi, Himura, Ryosuke, Maki, Jota, Mikami, Tomoya, Kishimoto, Hisataka, Ogawa, Shin, Nakahira, Youichi, Makari, Ken, Nakata, Masaki, Tsujie, Junya, Fujita, Hiroki, Ohzato
Publikováno v:
Gan to kagaku ryoho. Cancerchemotherapy. 45(13)
A 57-year-old female underwent abdominoperineal resection for rectal cancer. Although she received postoperative adjuvant chemotherapy, she had presacral recurrence with pain 26 months postoperatively. We provided palliative care in parallel with sys
Autor:
Kazumasa Fujitani, Hisato Kawakami, Naotoshi Sugimoto, Masahiro Goto, Taroh Satoh, Daisuke Sakai, Toshimasa Tsujinaka, Shunji Endo, Jin Matsuyama, Yusuke Akamaru, Youichi Makari, Toshio Shimokawa, Yutaka Kimura, Takao Tamura, Shigeyuki Tamura, Yukinori Kurokawa
Publikováno v:
Journal of Clinical Oncology. 38:379-379
379 Background: HERBIS-2 trial was a phase II trial where S-1 plus cisplatin (SP) and capecitabine plus cisplatin (XP) were compared in recurrent HER2 negative gastric cancer (GC) patients with recurrence free interval (RFI) by S-1containing adjuvant
Autor:
Taroh Satoh, Daisuke Sakai, Hisato Kawakami, Kenichi Nagai, Kenji Kobayashi, Hirokazu Taniguchi, Atsushi Takeno, Junichi Nishijima, Youichi Makari, Toshio Shimokawa, Shigeyuki Tamura, Naotoshi Sugimoto, Shunji Endo, Yutaka Kimura, Takao Tamura, Jin Matsuyama, Yukinori Kurokawa, Shugo Ueda, Kazumasa Fujitani, Ryohei Kawabata
Publikováno v:
Journal of Clinical Oncology. 36:102-102
102 Background: This phase II study aimed to investigate the safety and efficacy of XP compared to SP in the first-line treatment of HER2 negative AGC. Methods: Patients were randomly assigned to receive either SP (S-1 at 40–60 mg twice daily for 2
Autor:
Ryohei Kawabata, Shigeyuki Tamura, Yukinori Kurokawa, Junji Kawada, Atsushi Takeno, Yutaka Kimura, Youichi Makari, Toshio Shimokawa, Yuichiro Doki, Jin Matsuyama, Taroh Satoh, Daisuke Sakai, Kazuhiro Nishikawa
Publikováno v:
Journal of Clinical Oncology. 36:119-119
119 Background: Cisplatin and S-1 (CS) regimen is one of the standard chemotherapy as first-line for advanced gastric cancer. Docetaxel is a well-known agent with high anti-tumor effect for peritoneal metastasis from gastric cancer. A previous phase
Autor:
Hirohide Maruyama, Masaki Kashiwazaki, Masanori Naoi, Takayoshi Fujimoto, Keiji Uchide, Youichi Makari, Nobuo Tanaka, Sadayuki Doi
Publikováno v:
Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association). 62:722-725
上行結腸癌を合併したvon Recklinghausen病(以下R病)の1例を経験した.症例は51歳男性.前額部裂創にて当科受診時, R病が認められた.精査をした結果, CEAやや高値のため,大腸内視鏡を施行したと
Autor:
Nobuo Tanaka, Takayoshi Fujimoto, Hirohide Maruyama, Masaki Kashiwazaki, Sadayuki Doi, Youichi Makari, Keiji Uchide, Masanori Naoi
Publikováno v:
The Japanese Journal of Gastroenterological Surgery. 32:2659-2663
胃切除後の吻合部潰瘍による胃空腸横行結腸瘻は比較的まれで, 吻合部潰瘍の重篤な合併症の1つであり, 本邦では1931年から1998年まで71例の報告しかない. 十二指腸潰瘍穿孔に対して, 幽門
Autor:
Kazuyuki Okada, Masaaki Motoori, Youichi Makari, Shuji Takiguchi, Hiroshi Miyata, Morito Monden, Yoshiyuki Fujiwara, Itsuro Sohma, Jin Matsuyama, Akiko Yoshioka, Takushi Yasuda, Makoto Yamasaki, Yuichiro Doki
Publikováno v:
Oncology reports. 19(5)
The activation of the PI3K/Akt/mTOR pathway plays an important role in tumorigenesis and resistance to anticancer drugs. The aim of this study was to elucidate the role of the Akt/mTOR pathway in chemoresistance and the prognosis of patients with eso